On Thursday, Shares of Prestige Brands Holdings, Inc. (NYSE:PBH), lost -3.33% to $45.35.
Prestige Brands Holdings, declared results for the first quarter of fiscal year 2016, which ended June 30, 2015, and reconfirmed the outlook for the fiscal year formerly offered for revenues, adjusted earnings per share, and free cash flow.
Key first quarter highlights comprise:
- Revenues raised 31.9% to a record $192.1 million
- Free cash flow raised 46.5% to $42.7 million
- Organic sales growth of 3.7%, not taking into account the impact of foreign currency fluctuations
- Adjusted earnings per share raised 26.8% to $0.52
First Fiscal Quarter Ended June 30, 2015
Revenues for the first quarter of fiscal 2016 were $192.1 million, an improvement of 31.9% over the preceding year comparable quarter’s revenues of $145.7 million. These results reflect strong consumption levels across the Company’s core over-the-counter healthcare brands (OTC), our growing international business, in addition to the acquisitions of Insight Pharmaceuticals (Insight) and Hydralyte. Organic sales growth for the quarter was 3.7%, not taking into account the impact of foreign currency fluctuations.
Stated net income for the first quarter of fiscal 2016 totaled $26.2 million, or $0.49 per diluted share, an improvement of 56.4% over the preceding year comparable quarter’s results of $16.7 million, or $0.32 per diluted share. Adjusted net income for the first quarter of fiscal 2016 was $27.4 million, or $0.52 per diluted share, an improvement of 27.4% over the preceding year comparable period’s adjusted net income of $21.5 million, or $0.41 per diluted share.
Prestige Brands Holdings, Inc., through its auxiliaries, markets, sells, and distributes over-the-counter (OTC) healthcare and household cleaning products in North America, Australia, and internationally.
Shares of Hospitality Properties Trust (NYSE:HPT), inclined 0.39% to $25.76, during its last trading session.
Hospitality Properties Trust declared that its board of trustees has declared the regular quarterly dividend on HPT’s Series D Cumulative Redeemable Preferred Shares.
A distribution of $0.4453125 per Series D preferred share is payable on or about October 15, 2015, to holders of record at the close of business on September 30, 2015.
Hospitality Properties Trust is a real estate investment trust, or REIT, which owns a diverse portfolio of hotels and travel centers located in 45 states, Puerto Rico and Canada. HPT’s properties are operated under long-term administration or lease agreements. HPT is headquartered in Newton, Massachusetts.
Hospitality Properties Trust, a real estate investment trust (REIT), engages in buying, owning, and leasing hotels. The company’s hotels are operated as Courtyard by Marriott, Residence Inn by Marriott, Staybridge Suites by Holiday Inn, Candlewood Suites, AmeriSuites, Prime Hotels and Resorts, Homestead Studio Suites, TownePlace Suites by Marriott, and SpringHill Suites by Marriott or Marriott Hotels and Resorts.
At the end of Thursday’s trade, Shares of Insys Therapeutics Inc (NASDAQ:INSY), lost -1.84% to $33.58.
Insys Therapeutics declared that Michael Babich, President and Chief Executive Officer, and Darryl Baker, Chief Financial Officer, would present at the 10th Annual Wells Fargo Healthcare Conference, on Wednesday, September 9, 2015, at 8:50 a.m. EDT.
Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets Subsys, a proprietary sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients; and Dronabinol SG Capsule, a dronabinol soft gelatin capsule that is generic equivalent to Marinol, an approved second-line treatment for chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.
Finally, Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), ended its last trade with -4.47% loss, and closed at $116.25.
Ultragenyx Pharmaceutical declared that Sunil Agarwal, M.D., the company’s Chief Medical Officer, would be presenting at the Baird 2015 Health Care Conference on Wednesday, September 9, 2015 at 8:30am ET in New York.
Ultragenyx Pharmaceutical Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare diseases in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
